Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy. Issue 6 (10th June 2021)

• Record Type: Journal Article
• Authors: Hearn, Andrew P.; Hug, Oliver D.; Somani, Ziana A.; Kavanagh, Joanne; d'Ancona, Grainne; Roxas, Cris; Green, Linda; Thomson, Louise; Fernandes, Mariana; Kent, Brian D.; Dhariwal, Jaideep; Nanzer, Alexandra M.; Jackson, David J.
• Is Part Of: European respiratory journal. Volume 57:Issue 6(2021)
• Publication Date: 2021-06-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00166-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting interleukin (IL)-5 and IL-5R, respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3]. In a real-world setting, the clinical response to the anti-IL-5/5R mAbs mepolizumab and benralizumab in patients with severe eosinophilic asthma is independent of co-eligibility with the anti-IgE mAb omalizumab https://bit.ly/2NfAitP